Our Pricing

Wegovy vs Mounjaro UK: Which Weight Loss Injection Is Right for You?

When comparing Wegovy vs Mounjaro UK options, patients often ask which GLP-1 receptor agonist delivers superior weight loss results. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) are MHRA-licensed prescription injections proven in clinical trials to support significant weight reduction, yet they differ in mechanism, efficacy data, dosing schedules, and cost. This pharmacist-led guide compares both treatments across key clinical parameters to help you make an informed choice subject to prescriber approval.

How Wegovy vs Mounjaro UK Treatments Work: Mechanism of Action

Understanding the pharmacological difference between Wegovy vs Mounjaro UK injections begins with their receptor activity. Wegovy contains semaglutide, a selective GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the natural incretin hormone to slow gastric emptying, reduce appetite, and improve glycaemic control [1]. Mounjaro, by contrast, contains tirzepatide — the first dual GIP/GLP-1 receptor agonist licensed in the UK, activating both glucose-dependent insulinotropic polypeptide and GLP-1 pathways simultaneously [2].

This dual-agonist mechanism may explain why Mounjaro often demonstrates greater average weight loss in head-to-head trial data, though individual response varies considerably. Both medicines require subcutaneous injection once weekly and work by signalling satiety to the brain, slowing food transit through the stomach, and modulating insulin secretion in a glucose-dependent manner. Clinical trials show both treatments reduce body weight significantly when combined with a reduced-calorie diet and increased physical activity, subject to prescriber assessment and ongoing monitoring [1][2].

Wegovy vs Mounjaro UK Clinical Trial Data: Efficacy and Weight Loss Results

When evaluating Wegovy vs Mounjaro UK efficacy, the landmark STEP and SURPASS trial programmes provide robust comparative context. The STEP 1 trial demonstrated that adults using Wegovy 2.4 mg weekly achieved an average weight loss of 14.9% of baseline body weight over 68 weeks, compared to 2.4% with placebo [1]. Participants lost an average of 15 kg, with nearly one-third achieving at least 20% weight reduction.

Mounjaro's SURMOUNT-1 trial reported even higher average reductions: participants on the maximum 15 mg weekly dose lost an average of 20.9% body weight over 72 weeks, compared to 3.1% on placebo [2]. At the 10 mg maintenance dose, average weight loss was 19.5%. These figures position tirzepatide as potentially the most effective weight loss pharmacotherapy currently licensed in the UK, though real-world outcomes depend on adherence, lifestyle modification, and individual metabolic factors. Both treatments require ongoing clinical supervision and are not suitable for everyone.

Real-World Wegovy vs Mounjaro UK Outcomes in Clinical Practice

Beyond controlled trial settings, real-world Wegovy vs Mounjaro UK prescription data from NHS and private clinics suggest both agents deliver clinically meaningful weight loss when patients adhere to dosing schedules and lifestyle interventions. Cured Pharmacy's clinical team has observed that patients often tolerate the gradual dose escalation protocols well, with gastrointestinal side effects typically diminishing after the first 4–8 weeks. Individual response varies: some patients achieve target weight loss faster on Mounjaro, while others prefer Wegovy's established safety profile and longer UK market presence. Your prescriber will consider your medical history, BMI, comorbidities, and treatment goals when recommending either option.

Wegovy vs Mounjaro UK Dosing Schedules and Administration

The dosing regimen is a key practical consideration when comparing Wegovy vs Mounjaro UK injections. Wegovy follows a fixed monthly escalation: 0.25 mg weekly for four weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg weekly from week 17 onwards [1]. Each dose tier lasts four weeks to minimise gastrointestinal side effects and allow physiological adaptation.

Mounjaro uses a similar stepwise approach but offers more dose flexibility: starting at 2.5 mg weekly, escalating every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to a maximum of 15 mg weekly [2]. This broader dose range allows prescribers to tailor treatment intensity based on individual tolerance and weight loss progress. Both medicines are supplied in pre-filled single-dose pens for subcutaneous injection into the abdomen, thigh, or upper arm, and both require refrigeration before first use. Patients typically self-administer at home after initial training from a healthcare professional.

Side Effects: Wegovy vs Mounjaro UK Safety Profiles

Safety considerations are central to any Wegovy vs Mounjaro UK comparison. Both treatments share a similar adverse effect profile dominated by gastrointestinal symptoms: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort are the most frequently reported [1][2]. These effects are typically mild to moderate, occur most commonly during dose escalation, and often resolve within a few weeks as the body adapts.

Clinical trial data show approximately 44% of Wegovy users and 47% of Mounjaro users experienced nausea at some point during treatment, though severe cases leading to discontinuation were uncommon [1][2]. Rarer but serious risks include pancreatitis, gallbladder disease, hypoglycaemia (especially in patients taking other glucose-lowering medicines), and thyroid C-cell tumours observed in rodent studies (though no causal link has been established in humans). Both medicines carry a boxed warning regarding thyroid tumours and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Always disclose your full medical history during your online clinical assessment.

Managing Side Effects: Practical Guidance from UK Pharmacists

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) advises patients starting either Wegovy or Mounjaro to eat smaller, more frequent meals, avoid high-fat foods, and stay well hydrated to minimise nausea. Taking the injection on the same day each week, preferably after a light meal, can improve tolerability. If side effects become troublesome, your prescriber may slow the dose escalation or maintain a lower dose longer before advancing. Never adjust your dose without clinical guidance, and report persistent vomiting, severe abdominal pain, or signs of pancreatitis (upper abdominal pain radiating to the back) immediately.

Wegovy vs Mounjaro UK Pricing: Cost Comparison and Value

Price is often a deciding factor when patients evaluate Wegovy vs Mounjaro UK options. At Cured Pharmacy, Wegovy is available from £124.99 per four-week supply, while Mounjaro starts from £124.99 for the same period, reflecting the newer dual-agonist formulation and higher average efficacy in trials. Both prices include free online consultation with a UK-registered prescriber, next-day delivery across the UK, and 100% discreet packaging.

New patients can Save £20 off their first order using code Weightlossnew, making Wegovy accessible from just £124.99 initially. While Mounjaro carries a higher upfront cost, some patients find the potentially greater weight loss justifies the investment, particularly if they have not achieved target results with semaglutide-based treatments previously. Transparent pricing before consultation — with no hidden fees or subscription traps — is a core principle at Cured Pharmacy, ensuring you can budget confidently for long-term treatment. Both medicines require ongoing prescription and are not available over the counter.

Which Is Better: Wegovy vs Mounjaro UK for Your Weight Loss Goals?

There is no universal answer to which treatment wins the Wegovy vs Mounjaro UK debate — the optimal choice depends on your clinical profile, weight loss targets, budget, and tolerability. Mounjaro may be preferred if you seek maximum average weight reduction and are prepared for a higher cost and potentially more pronounced gastrointestinal side effects during initiation [2]. Wegovy remains an excellent first-line option with a well-established safety record, lower price point, and proven efficacy across diverse patient populations [1].

Your prescriber will assess your BMI, comorbidities (such as type 2 diabetes, hypertension, or obstructive sleep apnoea), previous weight loss attempts, contraindications, and personal preferences before recommending either treatment. Both require commitment to dietary modification and physical activity for best results — these are not standalone solutions. Cured Pharmacy's clinical team provides ongoing support throughout your weight loss journey, with regular follow-up consultations to monitor progress, adjust doses, and manage any adverse effects. Start your free online assessment today to discover which option suits you best, subject to prescriber approval.

How to Start Treatment: Wegovy vs Mounjaro UK at Cured Pharmacy

Beginning your Wegovy vs Mounjaro UK treatment at Cured Pharmacy is straightforward and fully remote. Complete our confidential online clinical questionnaire in under three minutes — our UK-registered prescribers review every submission individually, not via algorithm. If approved, your prescription is dispensed by our GPhC-registered pharmacy (9012511) and dispatched for next-day delivery in plain, discreet packaging. We supply only genuine UK-licensed medicines sourced from reputable wholesalers, never grey-market imports. Ongoing prescriptions are managed through your patient portal, with automatic reminders and flexible delivery scheduling. Contact our clinical support team on (+44) 116 4646009 if you have questions at any stage.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. [accessed 15 August 2026]
3. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
4. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
5. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.